Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 209, Issue 1-2, Pages 33-39Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2009.01.022
Keywords
EAE/MS; Chemokines; CCL2; CCR2
Categories
Funding
- MerckSerono
Ask authors/readers for more resources
Based on gene expression data, we tested the P8A-CCL2 variant of the chemokine CCL2, able to interfere with the chemotactic properties of the parental molecule, in relapsing-remitting (RR)-EAE SJL Only preventive treatment significantly delayed disease onset in a dose dependent manner. P8A-CCL2 administration, however, decreased demyelination, axonal loss and number of CNS infiltrating T cells and macrophages. Immunological analysis revealed that P8A-CCL2 does not act on Ag-specific T cell proliferation and does not interfere with the differentiation of IFN gamma-releasing effectors T cells. These results suggest that the therapeutic mechanism of P8A-CCL2 may rely on interference with immune cell recruitment. (C) 2009 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available